Keros Therapeutics, Inc. (KROS) Misses Q1 EPS by 14c

Keros Therapeutics, Inc. (NASDAQ: KROS) reported Q1 EPS of ($1.26), $0.14 worse than the analyst estimate of ($1.12).

For earnings history and earnings-related data on Keros Therapeutics, Inc. (KROS) click here.

You May Also Be Interested In

• Stitch Fix (SFIX) Tops Q4 EPS by 4c; Offers Guidance
• Visa deposits $405M into U.S. litigation escrow, adjusting stock rates
• Cintas beats estimates but stock edges lower